/

BNTC

Benitec Biopharma Inc.Closed

8.63−0.44 −4.85%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

8.89

Prev close

9.07

Day range

8.518.95

52-week range

8.5116.76

Volume

151.40K0.96×

Mkt cap

301.04M

P/E ttm

—

Fwd P/E

-0.92

EPS ttm

-0.9300

Div yield

0.00%

Earnings

Sep 14, 2026

From 52w high

−48.51%

Price Chart

Yahoo Finance · delayed

BNTCOct 13, 2026O 9.08H 9.08L 8.51C 8.63−0.44 (−4.85%)Vol 151.40K

SMA 5011.53
SMA 20011.80

1Y change −42.47% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BNTC Benitec Biopharma Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.11%
1 month: −29.20%
3 months: −33.51%
6 months: −34.87%
Year to date: −35.93%
1 year: −42.47%

Valuation & ownership

Market cap: 301.04M
Enterprise value: 121.83M
P/E (ttm): —
Forward P/E: -0.92
PEG ratio: —
Price / book: 1.68
Price / sales (ttm): —
EV / EBITDA: -2.38
EPS (ttm): -0.9300
EPS (forward): -9.42
Beta (5y monthly): 0.25
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 34.88M
Float: 18.45M
Short % of float: 10.23%
Short ratio (days): 13.26
Held by insiders: 2.51%
Held by institutions: 96.07%
Avg volume (3m): 157.93K
50-day average: 11.60
200-day average: 11.82
52-week change: −42.47%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 30.1
vs 50-day SMA: −25.17%
vs 200-day SMA: −26.84%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.17%
Realised vol (20d, ann.): 58.2%
From 52-week high: −48.51%
From 52-week low: +1.41%

ANR

Analyst Consensus

6 analysts

Consensus

Strong buy

1.14 on a 1 (strong buy) – 5 (sell) scale

Mean target

24.33

+181.96% implied

Low 17.00Median 24.50High 32.00

Recommendation trend

Now7 / 0 / 0
1m ago7 / 0 / 0

DES

About Benitec Biopharma Inc.

Yahoo Finance profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 24
Headquarters: Hayward, CA, United States
Website: benitec.com
Officers: Dr. Jerel A. Banks M.D., Ph.D. Executive Chairman & CEO
Ms. Megan Joan Boston B.Com., C.A. CFO & Secretary
Ms. Sophie Mukadam Chief Operating Officer
Dr. Michael Graham Head of Discovery & Founding Scientist

SEAS

Seasonality · BNTC

2014–2026 · monthly returns

Strongest month Feb +10.55%Weakest month Jun −13.16%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-9.6	-10.5	-2.3	13.1	-4.1	15.7	-12.5	3.9	-17.8	-13.7			−35.9%
2025	-9.0	10.6	2.4	4.5	13.0	-23.8	-6.6	21.1	6.0	16.6	-20.8	3.9	+6.7%
2024	-13.0	72.6	8.2	61.0	-9.5	-8.6	23.3	7.3	-0.6	14.4	-4.0	25.2	+291.0%
2023	35.3	30.4	-30.0	-4.3	19.9	-0.8	-24.2	-4.2	2.4	19.5	-11.9	1.6	+11.8%
2022	-6.5	-5.3	0.6	-35.8	-30.0	10.5	-22.5	-17.7	-49.7	-53.0	17.1	-17.1	−93.5%
2021	33.7	-21.4	64.1	-17.4	10.3	-9.8	-17.6	13.1	-9.8	2.5	-16.4	-14.4	−12.7%
2020	-10.4	13.3	-24.1	54.4	-19.8	8.4	-9.7	-2.5	-9.8	-57.2	10.0	1.4	−60.8%
2019	-7.1	29.8	8.3	2.0	-20.0	-53.2	13.5	-15.3	-1.3	-6.9	-18.6	-5.4	−66.0%
2018	22.3	-18.5	7.9	-17.7	1.1	-24.9	48.2	-3.7	-16.5	0.0	-13.1	-27.2	−49.3%
2017	12.4	56.4	2.6	-7.2	-12.9	-17.0	22.2	-9.3	5.9	31.3	1.8	2.1	+93.5%
2016	-10.7	-57.9	13.2	-13.5	-2.7	-11.9	34.7	6.6	-23.1	6.3	-1.2	4.1	−61.9%
2015	-23.1	6.0	-6.4	4.1	0.3	-13.5	24.9	-40.6	-22.8	-2.9	-25.3	-9.8	−74.2%
2014							-13.6	-4.8	-5.5	-41.5	24.2	25.5	−29.3%

INSD

Insider Activity · BNTC

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 28, 2026	Buchi J. KevinDirector	Stock Gift at price 0.00 per share.	51.8K	—
Dec 28, 2025	Suvretta Capital Management, LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 12.85 - 13.44 per share.	144.2K	$1.90M
Dec 21, 2025	Suvretta Capital Management, LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 11.24 - 12.08 per share.	46.1K	$538.97K
Nov 6, 2025	Suvretta Capital Management, LlcDirector and Beneficial Owner of more than 10% of a Class of Security	Purchase at price 13.50 per share.	1.48M	$20.00M
Mar 30, 2025	Suvretta Capital Management, LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 12.63 - 13.22 per share.	16.5K	$211.74K
Mar 25, 2025	Suvretta Capital Management, LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 13.00 per share.	900K	$11.70M
Mar 11, 2025	Buchi J. KevinDirector	Stock Gift at price 0.00 per share.	103.6K	—
Feb 26, 2025	Buchi J. KevinDirector	Conversion of Exercise of derivative security at price 3.86 per share.	51.8K	$200.00K
Dec 23, 2024	Suvretta Capital Management, LlcDirector and Beneficial Owner of more than 10% of a Class of Security	Purchase at price 10.98 - 11.25 per share.	47.5K	$527.17K
Dec 2, 2024	Suvretta Capital Management, LlcDirector and Beneficial Owner of more than 10% of a Class of Security	Purchase at price 9.60 per share.	42K	$403.20K
Nov 19, 2024	Suvretta Capital Management, LlcDirector and Beneficial Owner of more than 10% of a Class of Security	Purchase at price 9.73 - 10.22 per share.	41.4K	$416.62K

BNTC

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BNTC

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Benitec Biopharma Inc.

Seasonality · BNTC

Insider Activity · BNTC

Congress Trades · BNTC

Investors Holding BNTC

Investors Holding BNTC

Congress Trades · BNTC

Insider Activity · BNTC

Seasonality · BNTC

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Benitec Biopharma Inc.

Financial Snapshot

Earnings & Dividends

News